ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

TBIO Telesis Bio Inc

3,9082
-1,08 (-21,68%)
18 Jun 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Telesis Bio Inc TBIO NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
-1,08 -21,68% 3,9082 02:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
5,38 3,45 5,40 3,71 4,99
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
12.6.202423:00EDGAR2Form 8-K - Current report
11.6.202402:40EDGAR2Form SC 13D/A - General statement of acquisition of..
11.6.202402:30EDGAR2Form SC 13D/A - General statement of acquisition of..
10.5.202412:04EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09.5.202422:15EDGAR2Form 8-K - Current report
09.5.202422:05GLOBETelesis Bio Reports First Quarter 2024 Financial Results
06.5.202422:30EDGAR2Form 8-K - Current report
06.5.202422:05GLOBETelesis Bio Announces Reverse Stock Split
18.4.202415:00GLOBETelesis Bio Inc. announces strategic focus on game-changing..
28.3.202421:05GLOBETelesis Bio Reports Fourth Quarter and Full Year 2023..
06.3.202400:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.3.202400:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.3.202400:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.3.202402:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.3.202402:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26.2.202423:00EDGAR2Form 8-K - Current report
26.2.202415:15GLOBETelesis Bio Announces Select Preliminary Fourth Quarter..
30.11.202323:00EDGAR2Form 8-K - Current report
13.11.202322:32EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13.11.202322:32EDGAR2Form 8-K - Current report
13.11.202322:22GLOBETelesis Bio Reports Third Quarter 2023 Financial Results
09.11.202323:00EDGAR2Form 8-K - Current report
07.11.202315:00GLOBETelesis Bio to Report Third Quarter Financial Results on..
03.11.202317:00GLOBETelesis Bio Announces Commercial Release of Cell-free..
24.10.202322:30EDGAR2Form 8-K - Current report
28.9.202321:48GLOBETelesis Bio Announces Commercial Release of BioXp® NGS..
22.9.202323:00EDGAR2Form 8-K - Current report
29.8.202322:05GLOBETelesis Bio Appoints William J. Kullback Chief Financial..
29.8.202322:02EDGAR2Form 8-K - Current report
11.8.202312:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10.8.202322:17EDGAR2Form 8-K - Current report
10.8.202322:05GLOBETelesis Bio Reports Second Quarter 2023 Financial Results
04.8.202306:15EDGAR2Form EFFECT - Notice of Effectiveness
03.8.202323:00GLOBETelesis Bio to Report Second Quarter Financial Results on..
27.7.202323:28EDGAR2Form S-3 - Registration statement under Securities Act of..
07.7.202322:01EDGAR2Form 8-K - Current report